SciELO - Scientific Electronic Library Online

 
vol.39 número2Establecimiento de un material de referencia para interferón gamma humano recombinanteCausas de la no-trombólisis en el infarto agudo del miocardio y beneficios de su uso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Farmacia

versión On-line ISSN 1561-2988

Resumen

BRITO PASCUAL, Idalmis; BETANCOURT RODRIGUEZ, Blas Yamir; VALENZUELA SILVA, Carmen  y  LOPEZ SAURA, Pedro. Experience with the adverse reactions associated with recombinant alpha 2b interferon in hematology. Rev Cubana Farm [online]. 2005, vol.39, n.2, pp. 1-1. ISSN 1561-2988.

Alpha 2b interferon is a cytokine with antiviral, antiproliferative and immunomodulator activity that has proved to be efficient for the treatment of viral and neoplastic diseases, This paper is aimed at describing the frequency of adverse reactions associated with the administration of alpha R Heberon (recombinant alpha 2b interferon) in hematological diseases. The basic characteristics of the patients, as well as the frequency, intensity and causality relation of the reported events  were analyzed. The most common adverse effects were the manifestations of the gripal syndrome that included fever, chills, astenia, myalgia, anorexia and headache. These manifestations are transitory and respond to the treatment with non-steroideal antiinflammatory drugs. Most of the events were from mild to moderate intensity and did not require the suspension of the treatment. To conclude, alpha R Heberon is a relatively safe drug for the treatment of hematological disorders.

Palabras clave : alpha 2b interferon; alpha R Heberon; adverse events; causality relation.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License